Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms [18F]PRIMATX |
Target- |
Action modulators, enhancers |
Mechanism autotaxin modulators(Ectonucleotide pyrophosphatase/phosphodiesterase 2 modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 20 Aug 2019 | |
Pulmonary Fibrosis | Preclinical | United States | 20 Aug 2019 | |
Idiopathic Pulmonary Fibrosis | Preclinical | United States | 30 Jul 2019 | |
Idiopathic Pulmonary Fibrosis | Preclinical | United States | 30 Jul 2019 | |
Idiopathic Pulmonary Fibrosis | Preclinical | United States | 30 Jul 2019 | |
Idiopathic Pulmonary Fibrosis | Preclinical | Switzerland | 30 Jul 2019 | |
Melanoma | Preclinical | United States | 30 Jul 2019 | |
Melanoma | Preclinical | United States | 30 Jul 2019 | |
Melanoma | Preclinical | United States | 30 Jul 2019 | |
Melanoma | Preclinical | Switzerland | 30 Jul 2019 |